Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2025-07-02 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2025-07-02 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a stock purchase agreement) and unregistered sales of equity securities. It details the terms of the stock purchase agreement, payment structure, and use of proceeds. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a material event related to capital raising and stock issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive details about the financing agreement, supporting this classification with high confidence.
2025-06-26 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions the appointment of additional members to the scientific advisory board, which is a management or board-related update. There are no financial statements or detailed financial data included, and the document is not an earnings release, annual report, or other financial report. The document is not a proxy statement, voting results, or a merger announcement. The content fits best under Board/Management Information (MANG) as it announces changes in the company's advisory board members. The document length is about 6000 characters, which is consistent with a typical 8-K filing for such an event. Therefore, the classification is MANG with high confidence.
2025-06-24 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about a Master Clinical Supply Agreement with Roche, attached as an exhibit. There are no financial statements or detailed financial data included, only a description of the event and a forward-looking statement disclaimer. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial or governance report. It is a regulatory filing used to inform the market of a significant event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5981 characters, which is sufficient for a typical 8-K filing. Confidence is high due to the clear identification of the form and content.
2025-06-18 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 17, 2025, by MAIA Biotechnology, Inc. It reports the entry into a material definitive agreement involving inducement offer letter agreements with warrant holders to exercise warrants at a reduced price, resulting in issuance of common stock shares. The document details the transaction terms, expected proceeds, and regulatory exemptions for the securities issuance. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The content focuses on a capital raising transaction through warrant exercises, which is a financing activity. Therefore, the document is best classified as a Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing event, not merely an announcement or certification, so it is not RPA or RNS. Confidence is high due to clear identification of financing terms and transaction details.
2025-06-17 English
Regulatory Filings 2025
Regulatory Filings
2025-06-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.